Hepatotoxicity of contemporary antiretroviral drugs: A review and evaluation of published clinical data

Ashley O. Otto, Christina G. Rivera, John D. Zeuli, Zelalem Temesgen

Research output: Contribution to journalReview articlepeer-review


Contemporary antiretroviral agents afford enhanced potency and safety for patients living with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in the early stages of the HIV epidemic. While the safety profile has improved, adverse drug reactions still occur. We have segregated the antiretroviral agents used in contemporary practice into class groupings based on their mechanism of antiviral activity (non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, and entry inhibitors) while providing a review and discussion of the hepatoxicity seen in the most relevant clinical literature published to date. Clinical literature for individual agents is discussed and agent comparisons afforded within each group in tabular format. Our review will provide a summative overview of the incidence and medications associated with hepatic adverse reactions linked to the use of contemporary antiretroviral drugs.

Original languageEnglish (US)
Article number1263
Issue number5
StatePublished - May 2021


  • Antiretroviral therapy
  • Hepatotoxicity
  • Human immunodeficiency virus

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Hepatotoxicity of contemporary antiretroviral drugs: A review and evaluation of published clinical data'. Together they form a unique fingerprint.

Cite this